Flag of the European Union EU Clinical Trials Register Help

Clinical trials for glioma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    199 result(s) found for: glioma. Displaying page 7 of 10.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next»
    EudraCT Number: 2020-003089-38 Sponsor Protocol Number: FG001-CT-001 Start Date*: 2020-09-03
    Sponsor Name:FluoGuide A/S
    Full Title: An open-label, dose escalation, single-dose administration, multi-center phase I/II trial of FG001 (an imaging agent), in patients with glioblastoma scheduled for neurosurgery
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2009-017422-39 Sponsor Protocol Number: 26091 Start Date*: 2010-12-23
    Sponsor Name:European Organisation for Research and Treatment of Cancer
    Full Title: Randomized trial assessing the significance of Bevacizumab in recurrent grade II and Grade III gliomas. The TAVAREC trial.
    Medical condition: Recurrent grade II and grade III gliomas
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027744 Mixed astrocytoma-oligodendroglioma LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060971 Astrocytoma malignant PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026659 Malignant oligodendroglioma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) BE (Completed) GB (Completed) IT (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2016-002903-25 Sponsor Protocol Number: CC-4047-BRN-001 Start Date*: 2017-07-19
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 2 clinical study of pomalidomide (CC-4047) monotherapy for children and young adults with recurrent or progressive primary brain tumors.
    Medical condition: Recurrent or progressive primary brain tumors in one of four primary brain tumor types: high-grade glioma, medulloblastoma, ependymoma and diffuse intrinsic pontine glioma (DIPG
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Completed) FR (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-000900-16 Sponsor Protocol Number: UZB-BN-11-001 Start Date*: 2011-05-05
    Sponsor Name:UZ BRUSSEL
    Full Title: AA randomized phase II clinical trial on the efficacy of axitinib as a monotherapy or in combination with lomustine for the treatment of patients with recurrent glioblastoma
    Medical condition: • Patients with recurrent central nervous system glioblastoma (histologically confirmed WHO grade IV glioma), at documented recurrence/progression following prior treatment with surgery, radiation ...
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-004982-32 Sponsor Protocol Number: LIPDEP-001 Start Date*: 2007-06-27
    Sponsor Name:Medical University of Vienna, Department of Pedatrics
    Full Title: Cerebrospinal fluid (CSF) and plasma pharmocokinetics of liposomal cytarabine (DepoCyte®) after intrathecal administration in children with malignant brain tumors and leptomeningeal dissemination
    Medical condition: To measure concentrations of liposomal cytarabine in CSF and plasma over time after intrathecal administration of liposomal cytarabine in children of different age groups with a malignant brain tum...
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2021-005614-34 Sponsor Protocol Number: INFI-21-07 Start Date*: Information not available in EudraCT
    Sponsor Name:Helsinn Healthcare SA
    Full Title: A Phase 1b/2, Multicenter, Open-Label Study of Oral Infigratinib in Pediatric Subjects with Advanced Solid and Central Nervous System (CNS) Tumors (Phase 1b) and in Subjects with Recurrent or progr...
    Medical condition: Advanced solid and CNS tumors with selected FGFR1-3 mutations or fusions/rearrangements, inclusive of recurrent or progressive low-grade glioma (LGG) with selected FGFR1-3 mutations or fusions/rear...
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10025783 Malignant neoplasm of brain LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-005548-25 Sponsor Protocol Number: RNOP-12 Start Date*: 2008-07-28
    Sponsor Name:Freistaat Bayern, vertreten durch Klinikum der Universität Regensburg
    Full Title: Prospective, randomised (using minimisation), double-blind, placebo controlled study to evaluate the safety and efficacy of human normal immunoglobulin as a prophylactic agent against infections in...
    Medical condition: Patients with high-grade gliomas (world health organisation [WHO] grade III or IV) in the first relapse after first-line therapy including chemotherapy with or without nitrososurea, with a life exp...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-001453-23 Sponsor Protocol Number: G-85974806 Start Date*: 2023-01-12
    Sponsor Name:ASATE
    Full Title: Pilot safety study of neoadjuvant radiotherapy in patients with glioblastoma.
    Medical condition: Glioblastoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-013406-13 Sponsor Protocol Number: GBM-DC-2009 Start Date*: 2009-10-07
    Sponsor Name:Masaryk University
    Full Title: First Line Therapy of Glioblastoma Multiforme with Surgical Resection, Irradiation Therapy, Temozolomide and Additional Tumour-Lysate Pulsed Dendritic Cell Vaccination. A Feasibility Phase II Study...
    Medical condition: Glioblastoma Multiforme
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-005669-54 Sponsor Protocol Number: UKM2013-0034 Start Date*: 2020-06-02
    Sponsor Name:Universität Münster c/o Universitätsklinikum Münster, Geschäftsbereich Personal und Recht
    Full Title: Clinical safety study on 5-Aminolevulinic acid (5-ALA) in children and adolescents with brain tumours
    Medical condition: intra-axial brain tumor (malignant glioma, astrocytoma, malignant ependymoma, AT/RT, Oligodendroglioma, etc.)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006154 Brain tumor NOS LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-010004-28 Sponsor Protocol Number: ACNS0331 Start Date*: 2010-04-14
    Sponsor Name:COG
    Full Title: ACNS0331 A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy (18.00 Gy) and Chemotherapy in Children with Newly Diagnosed Standard Risk Medulloblas...
    Medical condition: Medulloblastoom standard risk
    Disease: Version SOC Term Classification Code Term Level
    12.0 10027107 Medulloblastoma LLT
    12.0 10027107 Medulloblastoma PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-015852-11 Sponsor Protocol Number: TC-FMISO-PET-06-1413 Start Date*: 2012-02-03
    Sponsor Name:Hospital Universitario Dr. Negrin
    Full Title: 18F-FMISO-PET in High Grade Gliomas: Assessment of Tumor Hypoxia and Effect of Spinal Cord Stimulation
    Medical condition: Hypoxia in malignant brain tumors: high grade gliomas
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-005219-16 Sponsor Protocol Number: GE-135-003 Start Date*: 2010-12-06
    Sponsor Name:GE Healthcare Ltd
    Full Title: A Phase 2, Open-label, Proof-of-concept Study to Assess the Ability to Detect Tumours and Angiogenesis via the Expression of avb3 Integrin Receptors by [18F]AH111585 PET Imaging
    Medical condition: Adult subjects with Primary or metastatic tumour lesion of one of the following types: high-grade glioma, including GBM, anaplastic astrocytoma, and anaplastic oligodendroglioma; lung cancer, inclu...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-004987-21 Sponsor Protocol Number: ONO-7579-01 Start Date*: 2017-09-13
    Sponsor Name:Ono Pharmaceutical Co., Ltd.
    Full Title: An open-label, multi-center, dose-escalation and expansion study to evaluate the safety and efficacy of ONO-7579 in patients with advanced solid tumors/ NTRK gene fusion positive advanced solid tumors
    Medical condition: Advanced solid tumors and Neurotrophic receptor tyrosine kinase (NTRK) gene fusion positive advanced solid tumors
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004864 10048683 Advanced cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-003595-16 Sponsor Protocol Number: GBM-MET Start Date*: 2023-05-23
    Sponsor Name:UNIVERSITÀ DEGLI STUDI MILANO BICOCCA
    Full Title: Phase 2, open-label, single-arm study on the use of metformin as adjunctive therapy in high-grade glioma
    Medical condition: IDH-wildtype glioblastoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-003539-31 Sponsor Protocol Number: EORTC-1635-BTG Start Date*: 2019-06-04
    Sponsor Name:European Organisation for Research and Treatment of Cancer
    Full Title: IDH mutated 1p/19q intact lower grade glioma following resection: Wait Or Treat? IWOT – A phase III study
    Medical condition: Histologically WHO grade II (diffuse) or III (anaplastic) astrocytoma, IDHmt without 1p/19q co-deletion (local diagnosis)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065869 Astrocytoma, low grade PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10002224 Anaplastic astrocytoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) DK (Prematurely Ended) FR (Prematurely Ended) AT (Completed) NO (Prematurely Ended) NL (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) GB (GB - no longer in EU/EEA) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-002123-10 Sponsor Protocol Number: 1200.120 Start Date*: 2015-04-18
    Sponsor Name:Boehringer Ingelheim España, S.A.
    Full Title: Phase I open label, dose escalation trial to determine the MTD, safety, PK and efficacy of afatinib monotherapy in children aged 2 years to <18 years with recurrent/refractory neuroectodermal tumou...
    Medical condition: Paediatric patients with recurrent//refractory high grade glioma (HGG), diffuse intrinsic pontine glioma (DIPG), low grade astrocytoma, neuroblastoma, ependymoma, medulloblastoma/primitive neuroect...
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10029091 Neoplasm of unspecified nature of endocrine glands and other parts of nervous system LLT
    18.0 100000004864 10029006 Neoplasm of uncertain behavior of brain and spinal cord LLT
    18.0 100000004864 10029050 Neoplasm of uncertain behaviour of connective and other soft tissue LLT
    18.0 100000004864 10028992 Neoplasm CNS LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Temporarily Halted) DE (Completed) GB (GB - no longer in EU/EEA) AT (Completed) FR (Completed) DK (Completed) IT (Completed) NL (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2022-000627-20 Sponsor Protocol Number: F8394-201 Start Date*: 2023-02-07
    Sponsor Name:Fore Biotherapeutics
    Full Title: A Phase 2 Master Protocol to assess the efficacy and safety of FORE8394, an inhibitor of BRAF class 1 and class 2 alterations, in participants with cancer harboring BRAF alterations
    Medical condition: Tumors harboring BRAF alterations
    Disease: Version SOC Term Classification Code Term Level
    23.0 10010331 - Congenital, familial and genetic disorders 10075648 BRAF gene mutation PT
    22.0 10022891 - Investigations 10075676 BRAF V600E mutation positive PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing) SE (Trial now transitioned) DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-004729-55 Sponsor Protocol Number: GD2CAR02 Start Date*: 2023-07-14
    Sponsor Name:IRCCS, OSPEDALE PEDIATRICO BAMBINO GESÙ DI ROMA
    Full Title: Phase I study of anti-GD2 Chimeric Antigen Receptor-Expressing T cells in pediatric and young adult patients affected by relapsed/refractory central nervous system tumors
    Medical condition: Relapsed/refractory malignant central nervous system tumors
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-010756-10 Sponsor Protocol Number: Index-CSBTE-01-09 Start Date*: 2009-05-19
    Sponsor Name:InDex Pharmaceuticals AB
    Full Title: Effect of an additional single dose of Kappaproct to corticosteroid treated patients with brain edema caused by brain tumor
    Medical condition: Patients with increasing clinical symptoms of brain edema caused by brain tumor or brain metatstasis, on maximum dose of corticosteroids will be asked to participate in the study. The brain edema m...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006121 Brain edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 03 06:13:50 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA